Unbiased Analysis of Today's Healthcare Issues
That is the title of the podcast episode I was on for AJMC’s Managed Care Cast. We discuss my recently published paper on insurance value in Duchenne’s Muscular Dystrophy (DMD). To learn more about research in DMD, check out AJMC’s DMD compendia page. The full podcast is below.
This is the title of a new paper I have out today at JMCP with co-authors Shanshan Wang, Jaehong Kim, Slaven Sikirica, and Alexander Sandhu with the subtitle “An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes“. The abstract is below: BACKGROUND: Heart failure (HF) is among the leading…
Check out my new publication with co-authors Suhail Thahir, Alexa Klimchak, Ivana Audhya, Lauren Sedita, and John Romley titled “Quantifying the Insurance Value for Rare Diseases: Duchenne Muscular Dystrophy” in AJMC. The abstract is below. Objectives: To quantify the magnitude of an ISPOR novel value element, insurance value, as applied to new treatments for a rare,…
That is the title of my article with Jaehong Kim, Shanshan Wang and Slaven Sikirica in the Journal of Comparative Effectiveness Research. The abstract is below. Aim: To assesses the cost–effectiveness of sotagliflozin for the treatment of patients hospitalized with heart failure and comorbid diabetes. Materials & methods: A de novo cost–effectiveness model with a Markov structure was created…
That is the title of my article with Melanie Whittington and Louis Garrison in STAT News. An excerpt is below: The changing landscape of drug pricing policy in the U.S. has implications for the global pace and direction of innovation. Drug policy changes are being influenced by perceptions of the value of novel medicines relative…
That is the title of a paper currently published (well, in pre-prints) at Value in Health. Co-authors include Jaehong Kim, Moises Marin MA, Sangeetha Ramsagar, Mark Lloyd Davies, Kyana Stewart, Iftekhar Kalsekar and Anil Vachani. The abstract is below: ObjectiveTo measure the value of increasing lung cancer screening rates for high-risk individuals and its impact…
That is the title of my new paper published today in Clinical and Applied Thrombosis/Hemostasis with co-authors Denise Clayton, Glorian Yen, Soyon Lee, Lincy Geevarghese, Yulin Shi, Luyang He, Ying Shen, and Anem Waheed. The abstract is below: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder commonly treated with complement inhibitors such as…
That is the title of my new paper out in ClinicoEconomics and Outcomes Research. This work was done with co-authors Kyi-Sin Than, Anmol Kanotra, Kirk W Kerr, Katie N Robinson, Michael C Willey. The abstract is below. Objective: To measure the economic impact of conditionally essential amino acids (CEAA) among patients with operative treatment for fractures.Methods: A…
That is the title of a study presented this week at the Obesity Week conference. This is work used a distributional cost effectiveness analysis approach for measuring the value of semaglutide 2.4 mg for the treatment of patients with obesity and overweight. It was conducted with co-authors Joshua Toliver, Mads Faurby, Jaehong Kim, Sanjana Muthukrishnan…
My paper with co-authors Shanshan Wang and Kirk Kirr just came out in the Journal of Long-Term Care titled Wound-Specific Oral Nutritional Supplementation Can Reduce the Economic Burden of Pressure Injuries for Nursing Homes: Results from an Economic Model. The abstract is below. Background To measure the cost savings and staff time savings of wound-specific…